Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Funaosu
- Development stage
- Unknown
- Lead developer
- Suzhong Pharmaceutical
- Administration
- Intravenous
01
Overview
Funaosu is a Traditional Chinese Medicine (TCM) injection developed by Jiangsu Suzhong Pharmaceutical Group for the treatment of cerebral infarction (ischemic stroke). It has undergone Phase 1 clinical evaluation in China (e.g., trial CTR20150799) to determine its safety, tolerability, and pharmacokinetic profile in healthy volunteers. As a botanical-based therapy, Funaosu is intended to address the pathological processes associated with ischemic stroke, potentially through mechanisms such as improving cerebral blood flow, reducing inflammation, or providing neuroprotection, although its specific molecular targets are not typically defined in early-stage clinical documentation.
- Brand names
- Funaosu
- Other names
- 辅脑苏
Beyond the preview
Go deeper on Funaosu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Funaosu.